Previous 10 | Next 10 |
U.S. Food and Drug Administration Approves BioMarin's VOXZOGO® (vosoritide) for Children Under 5 Years with Achondroplasia PR Newswire Expanded Indication in the U.S. Now Includes Children of all ages with Achondroplasia SAN RAFAEL, Calif. , Oct. 20...
2023-10-19 23:04:09 ET Summary During Q2 2023, BioMarin Pharmaceutical's revenues for the quarter has reached $595.3 million, a 12% YoY increase. The company's drug pipeline includes promising candidates for the treatment of rare diseases, such as severe hemophilia A and achondrop...
2023-10-19 08:15:00 ET Biotech stocks have been beaten down in 2023, with the sector off nearly 4% this year while the S&P 500 is up more than 15%. But some of the larger, better known biotech stocks have thrived -- Vertex Pharmaceuticals , Regeneron Pharmaceuticals , an...
BioMarin to Host Third-Quarter 2023 Financial Results Conference Call and Webcast on Wednesday, November 1, at 4:30pm ET PR Newswire SAN RAFAEL, Calif. , Oct. 17 , 2023 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques ...
2023-09-28 11:07:29 ET More on BioMarin Pharmaceutical BioMarin: Q2 2023 Confirmed My Bullish View BioMarin: More Growth Is Coming BioMarin upgraded at BMO after FDA nod for hemophilia A therapy Seeking Alpha’s Quant Rating on BioMarin Pharmaceutical ...
BioMarin to Present Data Showing Long-Term Benefit of VOXZOGO® (vosoritide) on Growth in Children with Achondroplasia at 2023 European Society for Paediatric Endocrinology (ESPE) Meeting PR Newswire Label Expansion Decisions Expected from U.S. and European Regulatory Auth...
BioMarin Receives Positive CHMP Opinion in Europe to Expand Use of VOXZOGO® (vosoritide) to Treat Children Aged 4 Months and Older with Achondroplasia PR Newswire European Commission Approval Decision Expected Q4 2023 Opinion Based on Positive Results from Global ...
BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York BioMarin to Present Innovative Pipeline at R&D Day on September 12th in New York PR Newswire Live Audio Webcast to Begin at 8:00 a.m. Eastern Time SAN RAFAEL, Calif. ...
BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th BioMarin to Present Pipeline at Upcoming R&D Day on Tuesday, September 12th PR Newswire BioMarin Leadership and External Medical Experts to Discuss 7 Product Candidates in Clinical Deve...
BioMarin to Participate in Three Upcoming Investor Conferences PR Newswire Citi's 18th Annual BioPharma Conference on September 6 at 3:30pm ET Morgan Stanley 21st Annual Global Healthcare Conference on September 11 at 10:00am ET Baird's 2023 G...
News, Short Squeeze, Breakout and More Instantly...
BioMarin Pharmaceutical Inc. Company Name:
BMRN Stock Symbol:
NASDAQ Market:
BioMarin Pharmaceutical Inc. Website:
2024-07-10 03:22:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-27 14:15:03 ET Scotiabank analyst issues UNDERPERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Underperform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus : BU...
2024-06-27 14:15:02 ET Wells Fargo analyst issues SECTOR PERFORM recommendation for BMRN on June 27, 2024 12:01PM ET. The previous analyst recommendation was Sector Perform. BMRN was trading at $82.885 at issue of the analyst recommendation. The overall analyst consensus...